Mangoceuticals, Inc. (NASDAQ: MGRX) announced that its MangoRx Direct and PeachesRx Direct weight‑management programs went live on November 13, 2025. The programs give patients access to Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy through the company’s existing telehealth platform, with a $99 monthly membership that covers unlimited virtual visits and coaching while medication costs are paid separately.
The launch was initially described as a partnership with Lilly and Novo Nordisk, but the company clarified that it has no direct contractual relationship with either manufacturer. Instead, Mangoceuticals works through an independent third‑party pharmacy‑benefits provider that facilitates cash‑pay access to the drugs. Both Eli Lilly and Novo Nordisk publicly denied any exclusive partnership, a clarification that has tempered enthusiasm for the initiative.
From a strategic perspective, the move diversifies Mangoceuticals’ revenue base beyond its core men’s wellness products and positions the company to capture a share of the high‑margin GLP‑1 market. However, the company’s financial profile—net losses of nearly $2 million in the September 30, 2024 quarter, a 45% decline in revenue from the same period a year earlier, and a current ratio of 0.1—highlights significant liquidity risk. The new program therefore represents both a potential growth engine and a substantial financial gamble.
CEO Jacob Cohen said the company is “working to make world‑class weight‑loss treatment simple and sustainable.” He added that the $99 membership includes unlimited telehealth visits and lifestyle coaching, while the GLP‑1 medications are available at fixed cash‑pay prices starting at $499 per month with home delivery. Cohen’s comments underscore the company’s focus on affordability and patient convenience, but they do not address the recent clarifications about the lack of direct manufacturer ties.
Investor sentiment has been volatile. The initial announcement sparked a strong positive reaction, driven by the perceived partnership with two blockbuster drug makers. After Eli Lilly and Novo Nordisk denied any direct relationship, the enthusiasm cooled sharply, reflecting concerns about the indirect nature of the access model and the company’s fragile financial footing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.